~~<i id='CC74FAF918'><strike id='CC74FAF918'><tt id='CC74FAF918'><pre id='CC74FAF918'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

fashion

author：comprehensive 2025-10-02 18:42:29 - browse：49

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Lack of health data on LGBTQ+ people has serious consequences

knowledge

hotspot

focus

entertainment

hotspot

focus

OLIVIERDOULIERY/AFPviaGettyImagesMedicalstudentsexperiencesignificantmentaldistress,includinghighrat

WSS

A new approach to psychiatric drug development

Ozempic has benefits for kidney disease as well as diabetes

IVF doctors demand details after CooperSurgical lawsuit

Lack of health data on LGBTQ+ people has serious consequences

$1 billion proposal to grow Boston, Massachusetts biotech

Medicare drug price negotiation hearing pits pharma v Biden admin

knowledge

fashion

knowledge

In age of alternative facts, a scholarly course on calling out crap

CommonSpirit Health keeps growing, even as it loses money

Trump demands the U.S. pay no more for drugs than other countries … again

Medicare drug price negotiation hearing pits pharma v Biden admin

Novavax promises a turnaround & Lilly roils the obesity market

State of the Union pitch: Bigger Medicare drug price negotiations

Drug repurposing or repositioning? The language matters

Readout LOUD podcast: possible new ALS drug, artificial wombs

Sports medicine is finally prioritizing gender equality

CDC's new outbreak response network to include Northeastern

hotspot

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

The public health thinking behind the CDC’s new Covid guidance

Senate HELP committee spars over health care workforce policies

Lack of health data on LGBTQ+ people has serious consequences

Changes to biosimilar regulatory framework must prioritize patients

focus

entertainment

hotspot

focus